Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe …
C Bally, S Thépot, B Quesnel, N Vey, F Dreyfus… - Leukemia research, 2013 - Elsevier
The effect of azacitidine (AZA) in therapy related MDS and AML (t-MDS/AML) is not well
established. 54 patients (42 t-MDS and 12 t-AML), 71% of whom had complex karyotype,
received AZA for at least one cycle (median 4 cycles). The overall response rate (ORR) was
39% in the whole cohort and 62% in patients who received≥ 4 cycles. One, 2 and 3 year OS
was 36%, 14% and 8% respectively. Female gender (p= 0.01) and ECOG 0–1 (p= 0.04)
were associated with significantly better OS, while karyotype and marrow blast percentage …
established. 54 patients (42 t-MDS and 12 t-AML), 71% of whom had complex karyotype,
received AZA for at least one cycle (median 4 cycles). The overall response rate (ORR) was
39% in the whole cohort and 62% in patients who received≥ 4 cycles. One, 2 and 3 year OS
was 36%, 14% and 8% respectively. Female gender (p= 0.01) and ECOG 0–1 (p= 0.04)
were associated with significantly better OS, while karyotype and marrow blast percentage …
